Navigation Links
Heart Procedure Reduces Need for Defibrillator Shocks

While study results are promising, they don't address benefits of drug therapy

WEDNESDAY, Dec. 26 (HealthDay News) -- A treatment that wipes out abnormal heart tissue reduces the number of shocks delivered to people who have defibrillators implanted after heart attacks, a new trial showed.

While those shocks do keep the heart going when it slips into abnormal rhythms, they are desirable to avoid not only because they are unpleasant to experience but carry hazards of their own, said study senior author Dr. Mark E. Josephson, chief of the cardiovascular division at Beth Israel Deaconess Medical Center in Boston.

"People with these devices have a lower quality of life because of the shocks and the fear of getting shocks," Josephson said. "With ablation, there was a marked reduction in any kind of therapy, and shocks specifically."

Ablation is a technique of identifying and eliminating cardiac tissue that can generate the kind of abnormal rhythm that sets the heart beating irregularly, so that a defibrillator shock is needed to restore normal heart rhythm.

The study led by Josephson included 128 people who had defibrillators implanted after heart attacks. Half of them underwent ablation, half did not. In an average follow-up period of 22.5 months, just eight of those who had ablation experienced defibrillator shocks, compared to 21 -- a full third -- of the group that did not have ablation.

And there was a marked reduction in deaths among those in the ablation group, Josephson said. Eleven of those who did not have ablation died, while there were just six deaths in the ablation group, he said. The numbers were too small to reach statistical significance, but Josephson described it as "a remarkable finding."

The study results are published in the Dec. 27 issue of the New England Journal of Medicine.

But the study did not address the issue of drug treatment to keep abnormal heart rhythm under control, said Dr. V.A. Mark Estes III, director of the cardiac arrhythmia center at Tufts New England Medical Center, and author of an accompanying editorial in the journal. None of the people in the trial were given anti-arrhythmia drugs, he said.

"Additional trials are needed to assess the comparative benefit of catheter ablation and anti-arrhythmic drugs, to identify which subgroups of patients are most likely to benefit, to evaluate the effect of operator expertise and to assess quality of life and cost," Estes wrote.

In addition, the trial "enrolled carefully selected patients and was conducted at highly experienced centers," Estes wrote. It's not clear whether the results would be as good at centers with less expertise, he said.

Drug treatment in such cases is problematical, Josephson said. "No data suggest that drugs would be effective," he said. "No drug has been shown to be particularly successful. Drugs also have side effects, and people must remember to take them. There needs to be some randomized trials showing that drugs reduce the need for defibrillator shocks."

Josephson said he was in full agreement with the need for expertise in applying ablation. "To identify potential sites and ablate them requires a skilled operator, electrophysiologists, training in mapping and in abrasion in particular," he said. "It all depends on the individual and the experience the individual has in this area. The procedure is intensive. We were fortunate in having a low incidence of any kind of side effect."

Given the right circumstances, benefits do flow to a person with an implanted defibrillator, Estes said. "These are really sick people who need these devices," he said. "But people don't like it even if they get an appropriate shock."

More information

A guide to ablation is offered by the U.S. Food and Drug Administration.

SOURCES: Mark E. Josephson, M.D., chief, cardiovascular division, Beth Israel Deaconess Medical Center, Boston; Dec. 27, 2007, New England Journal of Medicine

Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Drug for cluster headaches may cause heart problems
2. Use of certain lipid measures not more effective in predicting coronary heart disease
3. Restricting Blood Flow May Help Heart Bypass Patients
4. Urban Smog Tough on Young Adults Hearts
5. Stanford study highlights cost-effective method of lowering heart disease risks
6. Vitamin Es lack of heart benefit linked to dosage
7. Drug That Lowers Resting Heart Rate Being Tested
8. Heart Attack Boosts Diabetes Risk
9. Embryonic Stem Cells Repair Human Heart
10. U of M study: Early treatment can reverse heart damage
11. Embryonic Human Stem Cells May Help Repair Heart Muscle, Lab Study Shows
Post Your Comments:
Related Image:
Heart Procedure Reduces Need for Defibrillator Shocks
(Date:11/25/2015)... ... 2015 , ... The McHenry County law firm of Botto Gilbert Lancaster, ... Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant ... (2d) 130884WC. , According to court documents, Adcock testified that on May 10, 2010 ...
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new Android ... The new app features a more intuitive SleepScore™ that rates sleep quality on a ... The SleepScore is created by a proprietary algorithm. Beddit analyzes the data to provide ...
(Date:11/25/2015)... ... ... Today, Mothers Against Drunk Driving (MADD) learned that the number ... first time since 2011. In 2014, there were 9,967 fatalities involving an alcohol impaired ... Highway Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in 2014. ...
(Date:11/25/2015)... ... 2015 , ... Privately owned Contract Development and Manufacturing Organization ... current state of the art research, development and manufacturing facility outside of Fort ... capacity as well as to support its clients’ growing research and development and ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has focused on providing comprehensive solutions involving adult stem cell therapies to patients ... officially deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... DUBLIN , November 25, 2015 ... has announced the addition of the  ... 2015-2019"  report to their offering.  ... announced the addition of the  "Global ...  report to their offering.  ...
(Date:11/24/2015)... 24, 2015  Array BioPharma Inc. (Nasdaq: ... Officer, Ron Squarer , will present at ... York.  The public is welcome to participate in ... BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  , Ron ... 2015Time:1:30 p.m. Eastern Time Webcast: , ...
(Date:11/24/2015)... NEWS, Va. , Nov. 24, 2015  DILON ... they have signed an agreement for DILON to distribute ... geographies across the globe. The signing of this distribution agreement ... Discovery NM750b Molecular Breast Imaging system and is considered ... to provide better healthcare solutions for clinicians and their ...
Breaking Medicine Technology: